Peptide reviews on one yardstick.
Every compound scored on the same five dimensions, published evidence, mechanism plausibility, human data, vendor trust, regulatory posture, and ranked. Last database refresh 2026-04-29.
The peptides you can actually buy, ranked.
Collagen peptide powders and peptide skincare, held to the same evidence yardstick as the research compounds. Rankings set by the ingredient panel and the published trials; commissions never reorder a list.
The best collagen peptides
Our pick: Momentous Grass-Fed Collagen
See the rankings
The best peptide serums
Our pick: The Ordinary Copper Peptides 1%
See the rankingsStart with the evidence: Collagen peptides, the evidence · Peptides in skincare · Copper peptides (GHK-Cu)
The research-peptide literature, ranked.
Nine compounds in active rotation, scored on a 10-point composite. Updated quarterly.
Top four on every dimension.
Higher is better. Numbers are tabular, the methodology is on the methodology page, and yes, vendor trust counts because counterfeit risk is real.
New reviews and evidence files.
Every post is graded against the published literature and dated, and we revise with a note when the file changes.
Peptides for healing, sorted by how much evidence exists
Peptides for healing on the evidence: which repair-associated peptides have human data, which rest on animal wound-healing models, and why the strongest healing peptide is one most people already know.
Are peptides legal, and what that question actually means
Are peptides legal on the evidence: why the answer depends on approval status, the research-use-only label, and compounding rules, and why legal to sell is not the same as approved to use.
GHK-Cu before and after, separating photos from findings
GHK-Cu before-and-after on the evidence: what the skin and hair studies actually measured, why online transformation photos are not trial data, and a realistic view of the timeframes and magnitudes involved.
Topical versus injected GHK-Cu, matching claim to data
GHK-Cu topical versus injection on the evidence: why nearly all the human-relevant data is topical, why injectable use has no trial and raises copper-safety questions, and how to read the two routes honestly.
GHK-Cu dosing, what studies used rather than what to take
GHK-Cu dosage on the evidence: the topical concentrations used in skin and hair studies, why injectable dosing has no human trial behind it, and why the literature reports amounts rather than prescribing them.
TB-500 for recovery, what the thymosin beta-4 evidence supports
TB-500 for recovery on the evidence: the animal wound-healing and cardiac-repair data behind thymosin beta-4, the single completed human trial in a different tissue, and why athletic-recovery claims remain unproven.
Five shelves. Every review fits one.
Each shelf carries the reviews and the comparison tables for a single research domain.
Five dimensions, weighted, on every review.
Every score on Pepvise breaks down into the same five components. Read the full methodology if you want to argue with the weights, we will hear you out.
Read the full methodologySample size, replication count, and study design across PubMed, ClinicalTrials.gov, and FDA filings. Mouse-only literature gets capped.
Whether the proposed mechanism is consistent with established cell biology, or whether it is back-fitted to the marketing claim.
Trial phase, sample size, follow-up length, and the gap between rodent dose and the human dose actually studied.
Counterfeit incidence, third-party assay availability, regulatory posture of typical sources. Not an endorsement of any vendor.
FDA approval status, 503A/503B compoundability, WADA status, and the realistic legal pathway for a US patient or athlete.
On the pipeline.
Twelve reviews live, eight more in active drafting. Here is what is coming and when.
| Compound | Stage | Editor | Target pub |
|---|---|---|---|
| EpithalonEpitalon | Drafting | M. Otieno | 2026-06-12 |
| Thymosin α1 | Editor review | S. Han | 2026-06-19 |
| Selank | Pre-publication hold | M. Otieno | 2026-07-03 |
| Semax | Pre-publication hold | M. Otieno | 2026-07-10 |
One review a week. No vendor links. Ever.
When a new compound enters the database, or when an existing review gets a score change, subscribers hear about it first.
By subscribing you accept the privacy policy. One-click unsubscribe.